Literature DB >> 11966493

Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease.

L Cange1, E Johnsson, H Rydholm, A Lehmann, C Finizia, L Lundell, M Ruth.   

Abstract

AIM: To explore the effect of baclofen on oesophageal acid exposure in patients with gastro-oesophageal reflux disease. METHODS AND MATERIALS: Twenty patients with established reflux disease were included in this double-blind, randomized, crossover study. Baclofen, 40 mg, or placebo was given as a single dose with a washout period of 4 weeks. Symptoms were assessed by a visual analogue scale. Oesophageal pH was registered for 12 h and analysed for the whole period and for the 0-4-h, 4-8-h, 8-12-h and 2-h post-prandial periods.
RESULTS: Baclofen significantly reduced the number of reflux episodes during the 0-4-h (7.9 vs. 16.5, P < 0.0001; post-prandially: 6.0 vs. 11.2, P < 0.0001) and 0-12-h (46.5 vs. 73, P=0.0001; post-prandially: 18.8 vs. 29.3, P < 0.0001) periods. The fraction of time with pH < 4 was significantly lowered during the 0-4-h period (9.3 vs. 15.6, P=0.0019; post-prandially: 16.1 vs. 23.5, P=0.0083). Similar results were also obtained in patients with a hiatus hernia (n=13). Belching was significantly reduced (32 vs. 69 episodes, P < 0.01).
CONCLUSIONS: A single oral dose of 40 mg baclofen significantly reduced both the number of reflux episodes and the fraction of time with pH < 4, an effect primarily found during the first 4 h after dosing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11966493     DOI: 10.1046/j.1365-2036.2002.01250.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

1.  Potentiation of mouse vagal afferent mechanosensitivity by ionotropic and metabotropic glutamate receptors.

Authors:  James A Slattery; Amanda J Page; Camilla L Dorian; Stuart M Brierley; L Ashley Blackshaw
Journal:  J Physiol       Date:  2006-08-31       Impact factor: 5.182

2.  Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease.

Authors:  I-Rue Lai; Ming-Shiang Wu; Jaw-Town Lin
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

3.  Evaluation of peripheral versus central effects of GABA(B) receptor activation using a novel, positive allosteric modulator of the GABA(B) receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile.

Authors:  M Kalinichev; T Donovan-Rodriguez; F Girard; E Riguet; M Rouillier; B Bournique; H Haddouk; V Mutel; S Poli
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 4.  Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Authors:  Yu-Min Kung; Wen-Hung Hsu; Meng-Chieh Wu; Jiunn-Wei Wang; Chung-Jung Liu; Yu-Chung Su; Chao-Hung Kuo; Fu-Chen Kuo; Deng-Chyang Wu; Yao-Kuang Wang
Journal:  Dig Dis Sci       Date:  2017-11-06       Impact factor: 3.199

5.  Effects of (2R)-(3-amino-2-fluoropropyl)sulphinic acid (AFPSiA) on transient lower oesophageal sphincter relaxation in dogs and mechanism of hypothermic effects in mice.

Authors:  Anders Lehmann; Ann Aurell Holmberg; Ulhas Bhatt; Marianne Bremner-Danielsen; Lena Brändén; Susanne Elg; Thomas Elebring; Kevin Fitzpatrick; William B Geiss; Peter Guzzo; Jorgen Jensen; Gunilla Jerndal; Jan P Mattsson; Karolina Nilsson; Britt-Marie Olsson
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 6.  Neuro-regulation of lower esophageal sphincter function as treatment for gastroesophageal reflux disease.

Authors:  Anupender Singh Sidhu; George Triadafilopoulos
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

7.  Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors.

Authors:  P Malherbe; R Masciadri; R D Norcross; F Knoflach; C Kratzeisen; M-T Zenner; Y Kolb; A Marcuz; J Huwyler; T Nakagawa; R H P Porter; A W Thomas; J G Wettstein; A J Sleight; W Spooren; E P Prinssen
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

Review 8.  Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel?

Authors:  James Wise; Jeffrey L Conklin
Journal:  Curr Gastroenterol Rep       Date:  2004-06

Review 9.  Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.

Authors:  Marcello Tonini; Roberto De Giorgio; Fabrizio De Ponti
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.

Authors:  A F Ciccaglione; L Marzio
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.